Filtered By:
Source: Journal of Stroke and Cerebrovascular Diseases
Condition: Bleeding
This page shows you your search results in order of date.
Order by Relevance | Date
Total 88 results found since Jan 2013.
Neutrophil-to-lymphocyte ratio at admission is a risk factor for in-hospital gastrointestinal bleeding in acute ischemic stroke patients after dual antiplatelet therapy: A case control study
Gastrointestinal bleeding is a clinically important complication in acute ischemic stroke patients after dual antiplatelet therapy. The present study was to explore the association between neutrophil-to-lymphocyte ratio (NLR) and in-hospital gastrointestinal bleeding in acute ischemic stroke (AIS) patients who had received dual antiplatelet therapy.
Source: Journal of Stroke and Cerebrovascular Diseases - September 1, 2023 Category: Neurology Authors: Jiaming Huang, Foqiang Liao, Yeting Luo, Xu Shu Source Type: research
Tranexamic acid as a novel adjunct in the management of vessel perforation complicating Endovascular Clot Retrieval
To assess the safety and utility of tranexamic acid (TXA) as an adjunct salvage therapy in iatrogenic vessel perforation complicating endovascular clot retrieval. Iatrogenic vessel perforation and extravasation are known and potentially fatal complications of endovascular clot retrieval (ECR). Various methods of establishing haemostasis post perforation have been reported. TXA is widely utilised intraoperatively to reduce bleeding in various surgical specialities. The use of TXA in endovascular procedures has not been previously described in the literature.
Source: Journal of Stroke and Cerebrovascular Diseases - April 4, 2023 Category: Neurology Authors: Kerelus Morkos, Julian Maingard, Christen Barras, Hong Kuan Kok, Jonathan Hall, Jeremy Russell, Vincent Thijs, Lee-Anne Slater, Winston Chong, Ronil Chandra, Ashu Jhamb, Mark Brooks, Hamed Asadi Source Type: research
Factors affecting self-reported bleeding acceptance in acute ischemic stroke survivors on various types of antithrombotic therapy
Stroke causes long-term serious disability with global prevalence of 101 million people in 2019.1 Antithrombotic therapy is recommended for stroke secondary prevention depending on the acute ischemic stroke (AIS) subtype.2 One of the major causes of non-cardioembolic AIS is intracranial atherosclerosis, which requires single antiplatelet therapy (SAPT), mostly with aspirin.3,4 Dual antiplatelet therapy (DAPT) may reduce the risk of non-cardioembolic stroke by 29% in AIS attributable to severe intracranial stenosis when used for a limited period of time.
Source: Journal of Stroke and Cerebrovascular Diseases - November 16, 2022 Category: Neurology Authors: Gabriela Rusin, Jadwiga Kubica, Krzysztof Piotr Malinowski, Agnieszka S łowik, Anetta Undas Source Type: research
Safety of early antiplatelet administration in patients with acute ischemic stroke treated with alteplase (SEAPT-24)
This study aimed to examine the safety of early antiplatelet therapy administration within the first 24 h after alteplase.
Source: Journal of Stroke and Cerebrovascular Diseases - November 5, 2022 Category: Neurology Authors: Drew A. Wells, Lyndsey K. Davis, Omar Saeed, G. Morgan Jones, Cheran Elangovan, Andrei V. Alexandrov, Balaji Krishnaiah, Katherine L. March Source Type: research
Intraoperative imaging reveals spot sign with surgical correlate during early endoscopic ICH evacuation
Intracerebral hemorrhage (ICH) is the most devastating form of stroke. Intraoperative imaging and management of intracavity bleeding during early endoscopic ICH evacuation may mitigate rebleeding, hematoma expansion, and neurological worsening. Here we document a case of intraoperative spot sign, detected in the angio suite using cone beam CT with contrast protocol, in a patient with spontaneous supratentorial ICH undergoing evacuation 13 hours after last known well. The spot sign was detected after endoscopic evaluation of the evacuated hematoma cavity demonstrated sufficient hemostasis, but before completion of the case ...
Source: Journal of Stroke and Cerebrovascular Diseases - October 23, 2022 Category: Neurology Authors: Muhammad Ali, Jacopo Scaggiante, Vikram Vasan, Christina P. Rossitto, Johanna T. Fifi, Richard Aviv, J Mocco, Christopher P. Kellner Tags: Case Report Source Type: research
Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention
Early stroke occurrence after ischemic stroke or transient ischemic attack (TIA) remains a significant risk despite advances in secondary prevention. Ischemic stroke is largely a thromboembolic disease, and major efforts to reduce the early risk of recurrent stroke in patients with non-cardioembolic stroke have focused on antiplatelet strategies.1 Improvements in outcome have been associated with novel antiplatelet strategies, but significant residual risk of ischemic stroke and the potential for major bleeding, including intracranial hemorrhage, limit the effectiveness of these options.
Source: Journal of Stroke and Cerebrovascular Diseases - August 27, 2022 Category: Neurology Authors: Mukul Sharma, Carlos A. Molina, Kazunori Toyoda, Daniel Bereczki, Scott E. Kasner, Helmi L. Lutsep, Georgios Tsivgoulis, George Ntaios, Anna Czlonkowska, Ashfaq Shuaib, Pierre Amarenco, Matthias Endres, Hans Christoph Diener, David Gailani, Anja Kahl, Mar Source Type: research
P2Y12 reaction units and ischemic and bleeding events after neuro-endovascular treatment
To investigate the associations of perioperative P2Y12 reaction units (PRU) measured using VerifyNow with ischemic and bleeding events, and to determine the PRU threshold in the setting of elective neuro-endovascular treatment (EVT) for intracranial/extracranial vascular disease in patients taking aspirin and clopidogrel.
Source: Journal of Stroke and Cerebrovascular Diseases - July 15, 2022 Category: Neurology Authors: Kyohei Fujita, Shoko Fujii, Sakyo Hirai, Hiroto Yamaoka, Mariko Ishikawa, Jun Karakama, Kazunori Miki, Masataka Yoshimura, Shigeru Nemoto, Kazutaka Sumita Source Type: research
Pharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study
Major hemorrhagic complication incidence in patients with arterial fibrillation (AF), and treated with direct oral anticoagulants (DOACs), is lower than in vitamin K antagonist-treated patients.1 –5 Additionally, among DOACs, the direct oral thrombin inhibitor (dabigatran) and direct oral factor Xa (FXa) inhibitors (apixaban and rivaroxaban) seem to affect the coagulation system differently, which could provide distinct clinical outcomes.6,7 The results from the US6 and Denmark8 cohort stu dies suggest there is a minute, but notable difference in major bleeding complication incidence between dabigatran and FXa inhibitors.
Source: Journal of Stroke and Cerebrovascular Diseases - May 3, 2022 Category: Neurology Authors: Masahito Nakazaki, Shinichi Oka, Hirotoshi Magota, Ryo Kiyose, Rie Onodera, Ryo Ukai, Yuko Kataoka-Sasaki, Masanori Sasaki, Osamu Honmou Source Type: research
“Asymptomatic” Moyamoya Angiopathy: Is it Truly Asymptomatic?
Moyamoya angiopathy (MMA) is a chronic progressive occlusive intracranial vasculopathy characterized by angiographic findings of stenosis or occlusion at the terminal portion of the internal carotid artery (ICA) or proximal anterior cerebral artery (ACA) and/or middle cerebral artery (MCA) together with the abnormal vascular network (classically appears to be like “puff of smoke”) at the base of the brain.1,2 “Asymptomatic” MMA has been defined by previous absence of clinical and radiological evidence of ischemic or hemorrhagic episode in an angiographically proven MMA patient who are neurologically free, excluding...
Source: Journal of Stroke and Cerebrovascular Diseases - March 31, 2022 Category: Neurology Authors: Shambaditya Das, Biman Kanti Ray, Ritwik Ghosh, Souvik Dubey Source Type: research
Aspirin Use and Risk of Subdural Hematoma: Updated Meta-Analysis of Randomized Trials
Subdural hematomas are an uncommon, but a serious, bleeding complication of antithrombotic therapies. We update our previous inconclusive meta-analysis to better estimate the risk of subdural hematoma associated with aspirin use.
Source: Journal of Stroke and Cerebrovascular Diseases - June 13, 2021 Category: Neurology Authors: Robert G. Hart, Lesly A. Pearce, Philip B. Gorelick, Ben J. Connolly, Luciana Catanese Source Type: research
Anticoagulation Protocol for Secondary Prevention of Acute Ischemic Stroke Associated with Nonvalvular Atrial Fibrillation
Atrial fibrillation (AF) is a major risk factor for ischemic stroke and despite evidence for the efficacy of anticoagulation for secondary prevention of recurrent stroke in patients with AF,1 to date there is no established evidence regarding the timing for initiation of oral anticoagulants (OACs), including direct oral anticoagulants (DOACs), for secondary prevention of acute ischemic stroke associated with AF. Of concern in early initiation of OACs is the risk of recurrence balanced with the risk of hemorrhagic transformation (HT) after vascular reperfusion with reports of 3.6% symptomatic cerebral bleeding for acute use of OACs.
Source: Journal of Stroke and Cerebrovascular Diseases - June 6, 2021 Category: Neurology Authors: Teruo Kimura, Adam Tucker, Atsushi Nakagaki, Toshihide Sugimura, Shin Fukuda, Makoto Katsuno, Tsutomu Fujita, Naoto Izumi, Nozomi Suzuki, Kazuhiro Sako Source Type: research
Systemic Inflammation Response Index and Systemic Immune-inflammation Index for Predicting the Prognosis of Patients with Aneurysmal Subarachnoid Hemorrhage
An aneurysmal subarachnoid hemorrhage (aSAH) can result in disability and high mortality.1 Re-bleeding, poor admission neurologic status, thick SAH, vasospasm, and delayed cerebral ischemia (DCI) are known as predicting factors for exacerbated prognosis of aSAH.2 –5 Similar to other cerebrovascular diseases, aSAH can causes a pronounced peripheral inflammatory/immune response. Systemic changes are also associated with outcomes of patients with SAH.6,7 Although the exact mechanism has not yet been fully revealed, inflammation is known to plays an important role in the progress of aSAH by inducing early brain damage, vasos...
Source: Journal of Stroke and Cerebrovascular Diseases - May 22, 2021 Category: Neurology Authors: Seonyong Yun, Ho Jun Yi, Dong Hoon Lee, Jae Hoon Sung Source Type: research
An Enriched Environment Leads to Increased Synaptic Plasticity-Associated miRNA Levels after Experimental Subarachnoid Hemorrhage
Subarachnoid hemorrhage is a type of stroke caused by usually bleeding in the subarachnoid space with high morbidity and mortality.1,2 The cause is usually arterial aneurysm rupture and arterial hypertension. SAH also affects cognitive functions. Half of the patients may return to their daily lives in a year after SAH, but most of these patients often have problems in memory, executive functions, and speech functions in the future.3 Although long-term neurological disorders are thought to be caused by late-term cerebral ischemia due to vasospasm triggered by extravascular blood contact with the arteries, the molecular basi...
Source: Journal of Stroke and Cerebrovascular Diseases - April 15, 2021 Category: Neurology Authors: Fulya Buge Ergen, Didem Turgut Cosan, Turan Kandemir, İlknur Dag, Fezan Mutlu, Tevfik Erhan Cosan Source Type: research
Risk of Early Bleeding with Dual Antiplatelet Therapy in Acute Stroke and Transient Ischemic Attack Regardless of NIHSS Admission
Background: Dual antiplatelet therapy (DAT) is a therapeutic option for patients with minor ischemic stroke (IS) or transient ischemic attack (TIA). No study has evaluated the incidence of early bleeding in patients with moderate to major ischemic stroke. The current study aimed to analyze both the frequency of early bleeding and hospital morbidity related to DAT for either acute IS or TIA regardless of admission National Institute of Health Stroke Scale (NIHSS) score. Methods: This was a retrospective analysis based on data collected from a prospective data bank of a single center.
Source: Journal of Stroke and Cerebrovascular Diseases - March 4, 2021 Category: Neurology Authors: Valeria Cristina Scavasine, Rubens Mendes Barbosa, Francisco Diego Negrao Lopes Neto, Francisco Manoel Branco Germininani, Rodrigo Bazan, Viviane Flumignan Z étola, Ayrton Roberto Massaro, Marcos Christiano Lange Source Type: research
Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy
About 15% of patients with non-valvular atrial fibrillation might require percutaneous coronary interventions (PCIs) with stent placement to treat obstructive coronary artery disease. Dual antiplatelet therapy (DAPT) with acetylsalicylic acid (aspirin) and P2Y12 antagonist is recommended after PCI. Patients requiring DAPT also require treatment with oral anticoagulation for atrial fibrillation. We conducted a meta-analysis to identify the antithrombotic regimen associated with the lowest rate of bleeding and thromboembolic events in non-valvular atrial fibrillation after PCI.
Source: Journal of Stroke and Cerebrovascular Diseases - February 9, 2021 Category: Neurology Authors: Aaron Desai, Cesar Escamilla-Ocanas, Deepika Dilip, Hamidreza Saber, Rahul Damani Source Type: research
